• Patient-Derived Gastric Cancer Assembloids Enhance Drug Test

  2026-06-09

  This study presents a novel assembloid model integrating matched tumor organoids with stromal cell subpopulations from gastric cancer patients, enabling more physiologically relevant investigation of tumor–stroma interactions and drug responses. The approach highlights the importance of microenvironmental complexity in preclinical drug screening and resistance mechanism studies.

• Prochlorperazine in Translational Research: Mechanistic Dept

  2026-06-09

  Explore the advanced pharmacological profile of Prochlorperazine, a dopamine D2 receptor antagonist, and its unique translational research applications. This article provides a mechanistic deep dive, practical protocol guidance, and cross-domain insights not covered elsewhere.

• Cyclosporin A Beyond Immunosuppression: Multi-Modal Research

  2026-06-08

  Explore the multifaceted mechanisms and advanced research applications of Cyclosporin A, a pivotal immunosuppressant and cyclophilin inhibitor. This article uniquely connects its mitochondrial, apoptotic, and viral modulation effects to practical experimental workflows.

• Integrating ROS Assay Kits into Cutting-Edge Immunotoxicity

  2026-06-08

  Discover how the Reactive Oxygen Species Assay Kit leverages dihydroethidium (DHE) probes for advanced oxidative stress analysis in immunotoxicity studies—bridging mechanistic insights and practical assay design for redox biology.

• AZD2461: A Novel PARP Inhibitor for Advanced Breast Cancer R

  2026-06-07

  AZD2461 is a novel PARP inhibitor with nanomolar potency and the unique ability to overcome Pgp-mediated drug resistance. It induces robust cytotoxicity and G2 phase cell cycle arrest in breast cancer models. Its performance is supported by in vitro and in vivo benchmarks, making it a valuable tool for DNA repair pathway modulation.

• Toremifene vs Tamoxifen in Advanced Breast Cancer: Systemati

  2026-06-06

  A Cochrane systematic review rigorously compared toremifene and tamoxifen as oral selective estrogen receptor modulators for advanced breast cancer. The meta-analysis revealed no clinically significant differences in efficacy or safety between the two agents, informing evidence-based choices in hormone receptor modulation strategies.

• Redox Precision in Translation: Bardoxolone Methyl’s Strateg

  2026-06-05

  This article provides translational researchers with a mechanistic and strategic synthesis on leveraging Bardoxolone methyl (CDDO methyl ester) for redox pathway modulation. Integrating recent breakthroughs in thioredoxin system biology and translational oncology, it differentiates itself by providing evidence-based guidance on experimental design, competitive positioning, and emerging combinatorial strategies—bridging foundational biochemistry with actionable translational insights.

• 17-AAG (Tanespimycin): Applied HSP90 Inhibition Workflows

  2026-06-05

  17-AAG (Tanespimycin) empowers researchers to dissect HSP90-dependent oncogenic pathways, yielding precise, reproducible cytotoxicity and apoptosis data in diverse cancer models. This in-depth guide translates new discoveries in regulated cell death and membrane dynamics into actionable experimental protocols, troubleshooting strategies, and advanced applications—anchored by APExBIO’s proven reagent quality.

• Coumestrol: Phytoestrogen Estrogen Receptor Antagonist in RA

  2026-06-04

  Coumestrol offers advanced mechanistic leverage as a phytoestrogen estrogen receptor antagonist, uniquely enabling ferroptosis-driven modulation of pathogenic synoviocytes in rheumatoid arthritis research. This guide demystifies Coumestrol’s applied workflows, presents troubleshooting strategies, and highlights protocol parameters for reliable, high-impact endocrine disruption and nuclear receptor studies.

• Alpha-Ketoglutarate in Metabolic Reprogramming Research Work

  2026-06-04

  Alpha-ketoglutarate (α-KGA) is redefining metabolic reprogramming research and immune modulation, offering actionable leverage for enzyme system studies and tumor microenvironment exploration. This article details experimental workflows, advanced troubleshooting, and the latest translational insights, integrating breakthroughs from a recent Nature Communications study and complementary protocol resources.

• CYR61-Driven Migrasome Signaling Enhances IR BMSC Osteogenes

  2026-06-03

  The reference study identifies the extracellular matrix protein CYR61 as a key regulator of migration and osteoblastic differentiation in irradiated bone marrow mesenchymal stem cells (BMSCs), acting via migrasome-mediated delivery. These findings clarify mechanisms relevant to osteoradionecrosis repair and highlight molecular targets for regenerative therapies.

• Vitamin D Receptor Drives Ferroptosis and Salivary Hyposecre

  2026-06-03

  This study reveals that upregulation of the vitamin D receptor (VDR) promotes ferroptosis and impairs salivary secretion in female Sod1 knockout mice. The findings highlight a sex-specific mechanism linking oxidative stress, VDR activity, and ferroptosis-related gland dysfunction, offering a new perspective for therapeutic strategies targeting dry mouth and salivary gland disease.

• Ro 3306: Precision CDK1 Inhibition for G2/M Cell Cycle Studi

  2026-06-02

  Discover how Ro 3306, a potent CDK1 inhibitor, enables precise cell cycle G2/M phase arrest and advanced DNA repair mechanism studies. This article explores its molecular action and the latest insights for cancer research workflows.

• Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in

  2026-06-02

  Xie, Zhou, and Zheng employed a dual recombinase-mediated genetic tracing system to rigorously test whether new oocytes form in mice after birth under both physiological and injury conditions. Their findings provide clear evidence that postnatal neo-oogenesis does not occur in vivo, refining the foundational understanding of mammalian ovarian biology.

• Toremifene Citrate in Estrogen Receptor-Positive Breast Canc

  2026-06-01

  The reference study establishes Toremifene Citrate as a clinically validated oral selective estrogen receptor modulator, approved for treating locally advanced or metastatic, hormone receptor-positive breast cancer in postmenopausal women. Its comparable efficacy to tamoxifen and mechanistic insights into estrogen receptor modulation provide a robust foundation for translational and preclinical research applications.

15979 records 1/1066 page Next 12345 下5页 Last page